Canine Distemper in Dogs: Symptoms, Diagnosis, Vaccine, and Survival Guide
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Canine distemper virus (CDV) is a paramyxovirus belonging to the genus Morbillivirus, placing it in the same taxonomic group as the measles virus of humans and the rinderpest virus of cattle; the evolutionary and immunological relationship between CDV and measles means that dogs vaccinated with CDV-based vaccines have historically provided some cross-reactive immunity, and the CDV research platform contributed significantly to measles vaccine development; CDV is the most antigenically related animal paramyxovirus to human measles virus; the Morbillivirus genus is defined by its characteristic tropism for lymphoid tissue, epithelial cells, and the central nervous system, the production of multinucleated giant cells (syncytia), and the severe immunosuppression that accompanies infection; CDV is inactivated by heat (60 degrees Celsius for 30 minutes), ultraviolet light, and standard disinfectants (sodium hypochlorite, quaternary ammonium compounds, aldehydes), making environmental persistence brief under most outdoor conditions; however CDV can survive for several hours at room temperature in respiratory secretions and may survive longer in cold, moist, shaded environments.
- The host range of CDV is exceptionally broad compared to most canine pathogens: all members of the family Canidae are susceptible (domestic dogs, wolves, coyotes, foxes, jackals, African wild dogs); all members of the family Mustelidae (ferrets, mink, otters, weasels, martens, badgers, polecats, skunks); all members of the family Procyonidae (raccoons, coatis, ring-tailed cats, kinkajous); and some members of the large cat family Felidae (lions, tigers, leopards) have experienced documented CDV outbreaks with significant mortality; the Serengeti lion population experienced a severe CDV outbreak in 1994 that killed more than 1,000 lions; domestic cats have low susceptibility and do not develop significant clinical disease; in North America, raccoons are the most important wildlife reservoir for CDV and represent an ongoing endemic source of infection for unvaccinated domestic dogs; coyotes are similarly maintained; CDV outbreaks in raccoon and coyote populations are common in urban and suburban areas and the spillover risk to unvaccinated dogs in those environments is real and documented; ferrets are among the most susceptible species and develop severe, often fatal distemper without vaccination; all domestic ferrets should be vaccinated against CDV.
- CDV pathogenesis follows a predictable sequence after oronasal exposure: the virus first replicates in the tonsils and pharyngeal lymph nodes within 24 hours of exposure; by days 3 to 6 a cell-associated viremia carries CDV (primarily in B lymphocytes and T lymphocytes) to distant lymphoid organs including the spleen, lymph nodes throughout the body, thymus, and bone marrow; during this lymphoid phase (days 3 to 8) the dog may appear mildly ill or systemically normal but a severe lymphopenia develops as CDV preferentially infects and destroys lymphocytes; the severity of this lymphopenia is a critical determinant of clinical outcome: dogs with pre-existing CDV-specific antibody (from vaccination or prior natural infection) clear the cell-associated viremia before significant viral spread occurs and may remain subclinical; dogs with no pre-existing immunity and an inadequate humoral response allow the viremia to continue to a second phase in which CDV spreads to the epithelial cells of the respiratory tract, GI tract, urogenital tract, and skin; the most feared phase is CNS involvement, in which CDV reaches the central nervous system by transport across the blood-brain barrier in infected monocytes and by direct infection of cerebrovascular endothelium, producing the demyelinating encephalomyelitis that defines the neurological syndrome.
- Canine distemper produces two distinct types of neurological disease with different pathogeneses and clinical profiles: polioencephalomyelitis (also called distemper encephalitis) is the acute form that occurs during or shortly after the systemic illness and results from CDV replication within neurons and glial cells, producing direct cytolytic injury; the second type, demyelinating encephalomyelitis, is a subacute to chronic form driven predominantly by immune-mediated damage to myelin sheaths rather than direct viral cytolysis; this immune-mediated demyelination is analogous to the delayed neurological complications seen after measles in humans (subacute sclerosing panencephalitis); the clinical importance of distinguishing these two mechanisms is that the immune-mediated demyelinating form may be partially modified by immunosuppressive therapy (corticosteroids) and may follow a more chronic, progressive course with periods of partial remission; old dog encephalitis is a third, rare form of CDV-associated CNS disease in which viral persistence in the CNS of previously exposed or vaccinated older dogs leads to a progressive, chronic demyelinating syndrome months to years after initial exposure, without the systemic signs that characterize acute distemper; this form is clinically and pathologically distinct from acute distemper encephalitis and occurs in immunocompetent dogs with CDV-specific serum antibody, suggesting a failure of CNS immune surveillance rather than classical immunodeficiency.
- Two clinical findings are effectively pathognomonic for canine distemper and can allow a working clinical diagnosis without laboratory confirmation: myoclonus (also called chorea or distemper myoclonus) and hardpad disease; myoclonus is a rhythmic, involuntary, repetitive muscle contraction that typically affects one muscle group (most commonly the temporal muscles, masseter, or one limb) and persists even during sleep, which distinguishes it from tremors and seizures; it results from persistent CDV infection of lower motor neurons and, unlike other distemper neurological signs, often persists permanently even after the dog recovers from the acute systemic illness; hardpad disease is hyperkeratosis (abnormal thickening and hardening) of the nasal planum and digital footpads; the footpads in severe cases become so hard and overgrown that they develop a distinctive rough, cracked, almost horn-like texture; a dog with cracked, thickened footpads combined with respiratory illness and neurological signs in an unvaccinated dog is distemper until proven otherwise; CDV inclusion bodies (eosinophilic intranuclear and intracytoplasmic inclusions) in epithelial cells are pathognomonic on histopathology and can be seen in conjunctival scrapings under light microscopy in some cases.
- Modified live virus (MLV) CDV vaccines provide excellent long-duration protection and have dramatically reduced distemper mortality in vaccinated dog populations over the past 50 years; the standard core vaccine combination (DA2PP or DHPP: distemper, adenovirus type 2, parvovirus, parainfluenza) is among the most effective veterinary vaccines available; however, vaccine-induced immunity has an important vulnerability: maternal antibody interference; puppies receive passive immunity from their vaccinated mothers through colostrum and placental transfer, and these maternal antibodies protect the puppy during the first weeks of life but also neutralize attenuated vaccine virus in the MLV CDV vaccine, preventing the puppy from developing active immunity; the period when maternal antibodies have waned below protective levels but before successful vaccination occurs is the “window of susceptibility” during which puppies are at high risk; the timing of this window varies between individual puppies and cannot be predicted accurately from the dam’s titer; the standard approach of vaccinating at 6 to 8 weeks, 10 to 12 weeks, and 14 to 16 weeks with a booster at 1 year attempts to “catch” puppies in this window, but complete protection is not guaranteed until the 14 to 16 week dose is given and the puppy develops an active serological response.
The six-week-old Labrador Retriever puppy arrived at the veterinary clinic with a 3-day history of nasal discharge and mild cough; the foster home had acquired the puppy from a local shelter 2 weeks prior, and the puppy had received one distemper vaccination at the shelter intake exam. The discharge had changed from clear and watery on day 1 to thick, yellow-green, and purulent by day 3; the conjunctiva were red and swollen with mucopurulent ocular discharge; the puppy had a rectal temperature of 104.6 degrees Fahrenheit and was depressed and anorectic. Thoracic radiographs showed an interstitial to alveolar infiltrate in the caudal lung fields consistent with bronchopneumonia. The puppy was treated for bacterial bronchopneumonia and appeared to improve over the following week. Fourteen days later, the puppy was brought back with a new problem: the left thoracic limb was twitching rhythmically and repeatedly, the contractions persisting even when the puppy was resting and continuing through sleep. The footpads were noticeably thicker and harder than expected for a puppy of this age. RT-PCR on conjunctival swab material was positive for CDV RNA. The diagnosis was canine distemper with myoclonus: the rhythm of the twitching limb, the hardened footpads, the positive PCR, and the original respiratory illness together told a story that had been developing since the first day of shelter intake.
The Virus: Morbillivirus with a Broad Host Range
| Feature | Detail |
|---|---|
| Taxonomic classification | Order Mononegavirales; family Paramyxoviridae; genus Morbillivirus; single-stranded, negative-sense RNA genome approximately 15,690 nucleotides in length; enveloped virus with two surface glycoproteins: hemagglutinin (H protein, responsible for cell attachment via SLAM and Nectin-4 receptors) and fusion protein (F protein, responsible for membrane fusion and syncytium formation) |
| Related human pathogen | Measles virus (Morbillivirus hominis); CDV and measles virus share approximately 70 percent amino acid identity in the H, F, and N proteins; this antigenic relatedness explains partial cross-reactive immunity and allows CDV to serve as a large animal model for measles research |
| Environmental stability | Relatively fragile outside the host; inactivated by UV light, heat (60 degrees Celsius for 30 minutes), desiccation, and standard disinfectants; survives hours at room temperature in respiratory secretions; may survive up to 3 hours in fresh urine and feces; low risk of environmental contamination compared to parvovirus |
| Cellular receptors | SLAM (signaling lymphocyte activation molecule, CD150): the primary receptor on lymphocytes and macrophages, responsible for lymphoid phase replication and immunosuppression; Nectin-4 (poliovirus receptor-like protein 4): expressed on epithelial cells of the respiratory and GI tracts, responsible for the epithelial phase of infection and shedding; these receptor specificities explain the progression from lymphoid to epithelial tropism during infection |
| Inclusion bodies | Eosinophilic intranuclear and intracytoplasmic inclusion bodies in epithelial cells (conjunctival, bladder transitional epithelium, respiratory epithelium) and CNS cells (neurons, astrocytes); these inclusions represent sites of viral replication and are pathognomonic on histopathology; visible on cytological examination of conjunctival scrapings in some acute cases |
| Viral shedding | Infected dogs shed CDV in all secretions and excretions: nasal discharge (highest concentrations), ocular discharge, saliva, urine, and feces; shedding begins approximately 5 days after infection and may persist for months in surviving dogs with CNS involvement; CDV shedding occurs before clinical signs are apparent, making pre-clinical dogs a source of infection |
Clinical Phases of Canine Distemper
Phase 1: Initial Fever and Lymphoid Phase (Days 3 to 8)
The first clinical sign is a biphasic fever: an initial spike to 103 to 105 degrees Fahrenheit occurs approximately 3 to 6 days after infection as CDV replicates in tonsils and pharyngeal lymph nodes; this first fever often resolves within 1 to 3 days and is frequently missed or attributed to a minor illness; the second fever, occurring around days 7 to 14, accompanies the systemic viremia and cell-associated spread to distant lymphoid organs; lymphopenia is severe during the lymphoid phase and represents the primary determinant of clinical outcome; a complete blood count showing lymphopenia below 1,000 cells per microliter in an unvaccinated puppy with respiratory signs is a concerning finding that should prompt distemper testing; the dog may appear mildly depressed, anorectic, and feverish during this phase without specific localizing signs.
Phase 2: Respiratory and Gastrointestinal Phase (Days 8 to 21)
Dogs that fail to mount an adequate antibody response develop clinical signs referable to viral invasion of epithelial cells: serous nasal discharge that progresses to mucopurulent yellow-green purulent discharge as secondary bacterial infections (Bordetella bronchiseptica, Pasteurella multocida, Streptococcus canis) colonize the damaged respiratory mucosa; conjunctivitis with mucopurulent ocular discharge; harsh, productive cough with respiratory distress from bacterial bronchopneumonia; vomiting and diarrhea from GI tract involvement; anorexia and severe weight loss; the mucopurulent respiratory discharge in a puppy is often the first sign that brings the dog to veterinary attention and is the presentation most commonly confused with kennel cough or bacterial pneumonia; the critical differentiating factor is the vaccination history (or lack thereof) and the subsequent development of neurological signs.
Phase 3: Neurological Phase (Variable Onset, Days 7 to 42)
Neurological signs may develop concurrently with the respiratory/GI phase or follow it by 1 to 3 weeks; in some dogs, neurological signs are the presenting complaint without preceding respiratory illness (the neurotropic form of CDV); the spectrum of neurological signs reflects CDV involvement of different regions of the CNS:
- Myoclonus (chorea): rhythmic, repetitive, involuntary contractions of one muscle group, most often the temporal muscles or a limb; contractions are stereotyped, persistent during sleep, and often continue for life; pathognomonic for CDV encephalitis
- Cerebellar signs: intention tremor, dysmetria (goose-stepping gait), truncal ataxia, broad-based stance; reflect CDV demyelination of the cerebellar peduncles and cerebellar white matter
- Vestibular signs: head tilt, circling, nystagmus, ataxia from CDV involvement of vestibular nuclei or the inner ear
- Seizures: focal or generalized; may occur during the acute phase from direct neuronal injury or develop as a late complication of demyelination; “chewing gum seizures” (repetitive masticatory movements during a partial seizure) are classically associated with distemper encephalitis in some descriptions
- Progressive paresis and paralysis: from spinal cord involvement and demyelination; may progress to tetraplegia in severe cases
- Optic neuritis: blindness from CDV involvement of the optic nerves; may manifest as fixed, dilated pupils with absent menace response
Hardpad Disease
Hyperkeratosis of the nasal planum and digital footpads is a distinctive cutaneous manifestation of CDV infection reflecting the virus’s tropism for keratinizing epithelial cells; in affected dogs, the nasal planum loses its normal moist, soft texture and becomes dry, cracked, and thickened; the digital footpads undergo similar changes, becoming hard, rough, and fissured; in severe cases the footpads thicken to twice their normal depth and develop a horn-like texture; secondary bacterial infections in the fissures cause pain and lameness; the term “hardpad disease” was historically used before CDV was identified as the etiological agent of this syndrome; the combination of hardpad disease with neurological signs is effectively diagnostic for CDV in an unvaccinated dog.
Diagnosis
| Diagnostic Test | Sensitivity and Specificity | Notes |
|---|---|---|
| RT-PCR (blood, conjunctival swab, nasal discharge) | High sensitivity during viremic phase (days 3 to 14); lower sensitivity once viremia resolves; CSF PCR useful for CNS distemper | Test of choice for acute diagnosis; EDTA blood is best sample in early infection; conjunctival swabs are convenient and well-validated; false negatives occur after peak viremia resolves; post-vaccinal PCR positives possible for 1 to 3 weeks after MLV vaccination |
| Immunofluorescence (IFA) on conjunctival or tracheal smears | Moderate sensitivity (around 30 to 50 percent); high specificity | Rapid, inexpensive, available in-clinic at some practices; requires fresh smear preparation and fluorescent microscopy; sensitivity is insufficient to rule out CDV if negative; positive result is highly specific |
| Paired serology (ELISA or VN titer) | Reliable for confirming exposure in vaccinated vs. unvaccinated dogs; requires 2 to 4 week interval between samples | A single positive titer is uninterpretable in a vaccinated dog; a four-fold rise in titer between paired samples confirms active infection; useful for retrospective confirmation; not helpful for acute diagnosis |
| CBC with differential | Not specific; lymphopenia is supportive evidence in an unvaccinated dog with compatible signs | Lymphopenia below 1,000 cells per microliter in an unvaccinated puppy with respiratory signs should raise distemper suspicion; inclusion bodies (eosinophilic intracytoplasmic inclusions) visible in circulating lymphocytes are pathognomonic if found but are present in only a minority of cases |
| CSF analysis (neurological cases) | Elevated protein and mononuclear pleocytosis are present in most dogs with CDV encephalomyelitis; CSF RT-PCR is the preferred test for CNS distemper | CSF analysis helps confirm CNS involvement and rule out bacterial meningoencephalitis; normal CSF does not exclude CDV CNS disease; CSF PCR is more sensitive than serology for diagnosing CNS distemper |
| Histopathology (post-mortem) | Definitive; eosinophilic intranuclear and intracytoplasmic inclusion bodies in epithelial and CNS cells are pathognomonic | Perivascular cuffing and demyelination in white matter of the cerebellum and brainstem; intranuclear inclusions in neurons and glial cells; syncytia in lymphoid organs; submission of brain, lung, bladder, and lymph nodes recommended |
Differential Diagnosis
Several conditions mimic canine distemper and must be considered before committing to a CDV diagnosis:
- Rabies: neurological signs in an unvaccinated dog must trigger consideration of rabies before proceeding; rabies cannot be diagnosed in a living dog by any ante-mortem test that is universally accepted; a dog with progressive neurological signs and unknown vaccination history requires biosafety precautions pending test results
- Granulomatous meningoencephalomyelitis (GME): immune-mediated CNS disease in small breeds (Miniature Poodles, Maltese, Pugs); distinguishable by breed predilection, absence of systemic signs, MRI appearance, and CSF findings
- Bacterial meningoencephalitis: fever, neutrophilic pleocytosis on CSF, and rapid progression; responds to appropriate antibiotics
- Canine herpesvirus (CHV-1): affects neonatal puppies under 3 weeks old; fatal systemic hemorrhagic disease; relevant if neurological signs occur in the perinatal period
- Toxoplasma gondii: CNS toxoplasmosis can produce multifocal neurological signs; serology and PCR differentiate from CDV
- Neospora caninum: ascending progressive paralysis particularly affecting hindlimbs, often with rigid hyperextension (neosporosis); serology and PCR differentiate
- Hypoglycemia: seizures and weakness in puppies; blood glucose measurement rules out
Treatment
No Specific Antiviral Therapy
No commercially available antiviral drug has demonstrated reliable efficacy against CDV in clinical dogs; treatment is entirely supportive and symptomatic; the outcome is determined by the extent of CNS involvement and the dog’s own immune response; a dog with only respiratory and GI signs and no neurological involvement has a substantially better prognosis than one with established CNS disease; several experimental approaches (ribavirin, human intravenous immunoglobulin, recombinant CDV-specific antibodies) have been explored in research settings but none is currently available or validated for routine clinical use.
Supportive Care
Intravenous fluid therapy corrects dehydration and maintains perfusion in dogs with severe GI signs or respiratory distress; broad-spectrum antibiotics (amoxicillin-clavulanate, or enrofloxacin combined with amoxicillin in severe cases) are used to treat secondary bacterial pneumonia, which is a major contributor to mortality in CDV-infected dogs; mucolytics and nebulization help manage respiratory secretions; feeding tubes (nasogastric or esophagostomy) provide nutritional support in anorectic dogs; careful attention to nursing care (warmth, cleanliness, ocular hygiene) improves comfort and reduces secondary infections.
Neurological Symptom Management
Myoclonus management with methocarbamol (a centrally acting muscle relaxant, 44 mg/kg orally 3 times daily, maximum 330 mg/kg per day) reduces the severity of muscle contractions but does not eliminate them; diazepam at anti-anxiety doses may provide modest additional relief; myoclonus in CDV encephalitis rarely resolves completely and may be a permanent residual; seizure management follows standard protocols with phenobarbital (2.5 to 3 mg/kg orally twice daily) as the first-line anticonvulsant; levetiracetam (Keppra, 20 mg/kg orally 3 times daily) is increasingly used as an adjunct; the immunosuppressive dose of corticosteroids (prednisone 1 to 2 mg/kg per day) has been used by some clinicians for the demyelinating form of CDV encephalomyelitis to reduce the immune-mediated component of myelin destruction; this approach is controversial because immunosuppression may enhance CDV replication, but some dogs with predominantly demyelinating disease (confirmed by MRI showing white matter lesions without mass effect) may benefit transiently.
Vaccination
| Aspect | Details |
|---|---|
| Vaccine type | Modified live virus (MLV) vaccines using attenuated CDV strains (Snyder Hill, Lederle, Rockborn strains and their derivatives); recombinant canarypox-vectored CDV vaccines (Recombitek) provide safe, effective protection without risk of vaccine-associated encephalitis in immunocompromised dogs |
| Core status | Core vaccine: recommended for all dogs regardless of lifestyle; provided in combination vaccines (DA2PP or DHPP) that cover distemper, adenovirus type 2 (hepatitis), parvovirus, and parainfluenza |
| Puppy series | Vaccines at 6 to 8 weeks, 10 to 12 weeks, and 14 to 16 weeks; 14 to 16 week dose is critical because maternal antibody interference typically wanes by 12 to 16 weeks; a final dose at 1 year provides adult protection; some protocols add a 12-week dose for a 4-dose series in high-risk environments (shelters, pet stores) |
| Adult revaccination | Booster 1 year after completing the puppy series; subsequent revaccination every 3 years for most adult dogs; the American Animal Hospital Association (AAHA) guideline supports 3-year revaccination intervals for core vaccines after the 1-year booster based on duration of immunity studies |
| Duration of immunity | MLV CDV vaccines provide long-lasting immunity; seronegative titer tests do not necessarily indicate vaccine failure because cell-mediated immunity (CDV-specific memory T cells) provides protection even in the absence of high antibody titers; routine pre-vaccination titer testing is not recommended for healthy dogs on standard schedules |
| Vaccine-associated adverse effects | Post-vaccinal distemper encephalitis is an extremely rare complication of MLV CDV vaccination, occurring primarily in severely immunocompromised dogs (dogs on chemotherapy, neonates vaccinated before 4 weeks of age); recombinant canarypox-vectored vaccines avoid this risk entirely because they cannot revert to virulence; the MLV CDV vaccines may produce PCR-positive results for 1 to 3 weeks after vaccination, which can complicate diagnostic interpretation in vaccinated dogs with respiratory signs |
| Wildlife exposure risk | Dogs in raccoon-dense suburban or urban areas, and dogs that hunt or are used outdoors where contact with wildlife feces is possible, should be maintained on up-to-date CDV vaccination; CDV outbreaks in raccoon and coyote populations are common and represent a real spillover risk for unvaccinated dogs |
Prognosis
Prognosis for canine distemper is highly variable and depends primarily on the severity of CNS involvement: dogs with only respiratory and GI signs (no neurological signs) have a reasonable prognosis with aggressive supportive care, with survival rates of 50 to 75 percent in some case series; dogs with mild neurological signs (myoclonus alone, mild ataxia) have a guarded prognosis; some survive and maintain a reasonable quality of life with permanent neurological deficits; dogs with severe CNS disease (recurrent seizures, tetraplegia, progressive paresis, stupor) have a poor prognosis; euthanasia is often the most humane option for dogs with rapidly progressive CNS distemper that is unresponsive to supportive care; dogs that survive CNS distemper frequently have permanent residual signs, most commonly myoclonus; the quality of life with persistent mild myoclonus (single limb) can be acceptable; myoclonus affecting masticatory muscles can interfere significantly with eating and drinking.
Age-Specific Considerations
Puppies (6 Weeks to 6 Months)
- The highest-risk age group for CDV infection because of the maternal antibody interference window; a puppy whose mother was vaccinated and passed protective maternal antibodies via colostrum is protected for approximately the first 6 to 12 weeks of life; however, as maternal antibody titers wane, the puppy enters a window of susceptibility during which maternal antibodies have dropped below protective levels but CDV vaccine has not yet been given or has not generated a successful active immune response; this window typically occurs between 6 and 16 weeks of age and varies between individual puppies in the same litter based on the quantity of maternal antibody each received; shelters, pet stores, and puppy classes where unvaccinated puppies comingle are high-risk environments for CDV exposure during this window; the CDV vaccine should ideally complete its series (final dose at 14 to 16 weeks) before the puppy enters these environments
- Puppies with CDV typically have the most severe clinical signs because of their immature immune systems and their inability to mount an effective CDV-specific antibody response rapidly enough to limit viral spread; the respiratory and GI phases in puppies can be life-threatening because of the combination of severe bacterial bronchopneumonia (puppies lack the immune reserve to combat secondary bacterial infections effectively), diarrhea-associated dehydration, and rapid deterioration; aggressive inpatient supportive care (IV fluids, IV antibiotics, nutritional support) is required for most puppies with systemic distemper
- Puppies under 3 weeks of age should not receive MLV CDV vaccines because their CNS is immature and post-vaccinal distemper encephalitis is a real risk; the earliest safe vaccination age for MLV CDV vaccines is 6 weeks; in very high-risk environments (CDV outbreak in a shelter), recombinant canarypox-vectored CDV vaccines can be used in puppies as young as 4 to 6 weeks because the canarypox vector cannot replicate in mammalian cells and poses no risk of vaccine-associated encephalitis regardless of the puppy’s immune status
Adult Dogs (1 to 8 Years)
- Well-vaccinated adult dogs have robust CDV-specific immunity and rarely develop clinical distemper; when distemper occurs in adult dogs, it is almost always in unvaccinated dogs or dogs with vaccine gaps; adult dogs without documented vaccination history or with lapsed vaccines (several years since last CDV booster) who live in areas with active wildlife CDV reservoirs (raccoon-dense suburban areas) face real exposure risk; CDV vaccination should be current in all dogs, regardless of indoor/outdoor status, because indoor dogs can be indirectly exposed through raccoon feces tracked in on shoes and clothing
- Adult dogs with distemper may be presumed to have kennel cough, bacterial pneumonia, or other respiratory disease based on their age and vaccination status assumptions; a careful vaccination history is critical in any adult dog with respiratory illness and atypical features (unusually severe lymphopenia on CBC, mucopurulent bilateral ocular discharge, footpad changes); the RSAT serology test is unreliable for CDV diagnosis in vaccinated adult dogs because vaccine-induced titers cannot be distinguished from infection-induced titers; RT-PCR on conjunctival swabs is more diagnostically useful in adult dogs with suspected CDV
- Hunting dogs, farm dogs, and dogs living in areas with high wildlife CDV prevalence should be confirmed to have current CDV vaccination before the hunting season or before entering environments with high raccoon and fox populations; the 3-year revaccination schedule assumes that the dog received the complete initial series and 1-year booster; dogs with unknown or incomplete prior vaccination history should receive a 2-dose series separated by 3 to 4 weeks followed by annual revaccination for 1 year before transitioning to the 3-year schedule
Senior Dogs (9 Years and Older)
- Old dog encephalitis is a rare form of CDV-associated CNS disease that occurs in older dogs, including previously vaccinated dogs, and represents a distinct syndrome from acute distemper encephalitis; the pathogenesis involves CDV persistence in the CNS long after the acute infection has resolved, with progressive immune-mediated demyelination; clinically, affected dogs develop slowly progressive neurological signs (ataxia, behavioral changes, dementia-like cognitive changes, visual deficits) without the respiratory illness or fever of acute distemper; CDV antigen and RNA can be detected in brain tissue of affected dogs at post-mortem examination, and serum CDV titers are often positive; old dog encephalitis is rare but should be included in the differential diagnosis of any senior dog with unexplained progressive encephalopathy
- The CDV core vaccination schedule applies to senior dogs as to younger adults; immunosenescence (the decline in immune function with age) may reduce the magnitude of vaccine-induced antibody responses in some senior dogs, but the clinical significance of reduced vaccine titers in aged dogs with years of prior CDV immunity is unclear; most senior dogs with complete prior vaccination histories have adequate long-term CDV protection from memory B and T cells even if current antibody titers are lower than those in younger adults; a titer test can reassure owners of senior dogs with uncertain vaccination histories that CDV-specific immunity is present
- Senior dogs with other systemic diseases (cancer, chronic kidney disease, Cushing’s disease, diabetes) may be on immunosuppressive medications (prednisone, cyclosporine, azathioprine) that could theoretically reduce CDV vaccine responses; MLV CDV vaccines should generally be avoided in severely immunocompromised dogs (those on immunosuppressive doses of medications); recombinant canarypox-vectored CDV vaccines are safe in immunocompromised dogs because the vector cannot replicate, and are preferable for this population
Myths and Facts About Canine Distemper
My dog is fully vaccinated and only goes to the dog park, so there is no risk of distemper and we can skip the booster this year.
CDV vaccination provides excellent protection but requires maintenance; the 3-year adult revaccination schedule is evidence-based and appropriate, but skipping multiple boosters over several years allows immunity to wane; dog parks, boarding facilities, and any environment shared with dogs of unknown vaccination status carries CDV exposure risk; raccoon and coyote feces in outdoor areas represent a wildlife reservoir source; maintaining current core vaccination is simple, inexpensive, and far less costly than treating distemper; the AAHA guidelines recommend against exceeding the 3-year booster interval for CDV without a titer test confirming protective antibody levels.
If my dog develops the twitching from distemper, it will eventually stop on its own as the dog recovers.
Distemper-associated myoclonus (rhythmic, involuntary muscle twitching) is caused by permanent damage to lower motor neurons from CDV replication; unlike the other signs of acute distemper, myoclonus very rarely resolves completely and in most dogs persists for life; the muscle contractions may decrease slightly in frequency over time but the underlying neuronal damage is permanent; this distinguishes distemper myoclonus from the tremors and muscle jerks seen with other treatable neurological conditions; management with methocarbamol can reduce severity but does not cure the myoclonus; owners should be counseled honestly that this sign is permanent before committing to long-term management.
Distemper is essentially eliminated in the US and is only a concern in developing countries with low vaccination rates.
CDV remains endemic in North American wildlife populations, particularly raccoons, coyotes, and foxes; CDV outbreaks in raccoon and coyote populations occur regularly in urban and suburban areas across the US, and these wildlife cases represent an ongoing spillover risk to unvaccinated domestic dogs; shelter dogs and dogs from breeding operations with poor vaccination compliance continue to develop distemper in the US; while vaccination has dramatically reduced distemper in well-vaccinated populations, the disease has not been eliminated and should not be dismissed as a historical problem.
Red Flags: Signs Requiring Urgent Veterinary Evaluation
- Rhythmic, repetitive muscle twitching in a puppy or unvaccinated dog, particularly if the contractions continue during sleep: this pattern is essentially pathognomonic for distemper myoclonus and requires immediate veterinary evaluation; myoclonus occurring during sleep is a key feature that distinguishes distemper-associated tremors from other movement disorders; note the affected muscle group, frequency, and duration of contractions, and video the episode to show the veterinarian if it has resolved by the time you arrive
- Thick, yellow-green nasal and ocular discharge combined with fever and cough in an unvaccinated puppy or dog: the bilateral mucopurulent discharge from both eyes and nose simultaneously in an unvaccinated puppy should trigger distemper suspicion before the neurological signs develop; early diagnosis and supportive care, begun during the respiratory phase, gives the best chance of limiting neurological progression; do not dismiss bilateral purulent nasal and ocular discharge in a young puppy as routine upper respiratory infection without ruling out distemper
- Thickened, hardened, or cracked footpads in a young unvaccinated dog: normal footpads in a puppy or young dog are soft and pliable; footpads that are noticeably hard, rough, thickened, or cracked beyond normal wear in a young dog should prompt a distemper evaluation, particularly in combination with any history of recent respiratory illness; hardpad disease is a pathognomonic cutaneous sign of CDV infection that specifically implicates the virus
- Seizures in a puppy or unvaccinated dog with a recent history of respiratory illness: new-onset seizures in a dog with a preceding respiratory illness and no other cause identified warrant distemper testing as a priority before attributing the seizures to idiopathic epilepsy; CDV encephalitis can produce its neurological signs 1 to 4 weeks after the respiratory phase resolves, during which time the owner may have forgotten or not mentioned the earlier illness
- Progressive rear limb weakness with ascending paralysis in an unvaccinated dog: CDV myelopathy produces a progressive ascending weakness that can be confused with acute intervertebral disc herniation, degenerative myelopathy, or other spinal cord disease; the presence of any additional distemper signs (nasal discharge, ocular discharge, fever, footpad changes) with spinal cord signs should prompt CDV testing
US Cost Overview for Canine Distemper
| Service | Typical US Cost |
|---|---|
| Veterinary examination | $60 to $150 |
| DA2PP or DHPP core vaccine (preventive) | $20 to $45 per dose |
| RT-PCR for CDV (conjunctival swab or blood) | $60 to $140 |
| CSF tap and analysis (neurological cases) | $300 to $600 |
| Complete blood count and chemistry panel | $150 to $300 |
| Thoracic radiographs (pneumonia assessment) | $150 to $350 |
| Brain MRI (CNS distemper evaluation) | $1,500 to $3,000 |
| Inpatient hospitalization (IV fluids, antibiotics, nursing) | $800 to $2,500 per day for critical cases |
| Methocarbamol (myoclonus management, 30-day supply) | $30 to $80 |
| Phenobarbital (seizure control, 30-day supply) | $20 to $60 |
| CDV serology titer test | $50 to $100 |
| Total cost, mild respiratory case, outpatient | $400 to $1,200 |
| Total cost, severe CNS case, inpatient | $3,000 to $10,000 or more |
Frequently Asked Questions About Canine Distemper
What is canine distemper?
Canine distemper is a severe, highly contagious viral disease caused by canine distemper virus (CDV), a paramyxovirus in the genus Morbillivirus, the same virus family as human measles. CDV infects dogs and a wide range of other mammals including raccoons, ferrets, and large cats. It attacks the respiratory, GI, and nervous systems, producing a multisystemic illness that can be fatal. Vaccination with the core DA2PP or DHPP combination vaccine prevents infection.
What are the symptoms of canine distemper?
Canine distemper progresses through stages: initially fever, lethargy, and loss of appetite; then thick mucopurulent nasal and eye discharge, cough, and GI signs (vomiting and diarrhea); and finally neurological signs in many dogs, including rhythmic muscle twitching (myoclonus), seizures, ataxia, paresis, and blindness. Thickened, hardened footpads (hardpad disease) and nasal planum hyperkeratosis are pathognomonic cutaneous signs.
How is canine distemper treated?
No specific antiviral drug is available for CDV. Treatment is supportive: intravenous fluids for dehydration, broad-spectrum antibiotics for secondary bacterial pneumonia, nutritional support, and symptomatic management of neurological signs. Methocarbamol manages myoclonus; phenobarbital or levetiracetam controls seizures. Prognosis depends heavily on the severity of CNS involvement; dogs with only respiratory signs have better outcomes than those with established neurological disease.
Can a vaccinated dog get distemper?
Vaccine failures are rare but possible. The most common scenarios are puppies in the maternal antibody interference window (6 to 16 weeks, before the vaccine series is complete), dogs with lapsed vaccination schedules, and severely immunocompromised dogs with inadequate vaccine responses. A well-vaccinated adult dog on a current 3-year booster schedule very rarely develops distemper. Persistent CDV immunity from vaccination protects through memory T cells even when serum antibody titers appear low.
Is canine distemper contagious to cats or humans?
CDV is in the same genus as the human measles virus but does not infect humans; it is not a zoonotic disease. Domestic cats have low susceptibility to CDV and do not develop significant clinical disease from exposure to infected dogs. However, CDV infects ferrets severely, so ferrets in households with a distemper-infected dog must be kept strictly separated. CDV also infects raccoons, coyotes, foxes, and some large wild cats.
Will my dog’s muscle twitching from distemper go away?
Distemper myoclonus is caused by permanent damage to lower motor neurons from CDV replication. Unlike the respiratory and GI signs of distemper, myoclonus very rarely resolves completely and in most dogs persists for life. The twitching may decrease slightly in frequency over months but the underlying neuronal damage is irreversible. Methocarbamol can reduce the severity of contractions. Dogs with mild, single-limb myoclonus can maintain a reasonable quality of life; myoclonus affecting masticatory muscles can significantly impair eating.
How do I protect my puppy from distemper before they are fully vaccinated?
Until the puppy vaccination series is complete (final dose at 14 to 16 weeks), keep your puppy away from unvaccinated dogs, shelter environments, pet stores, and any areas frequented by wildlife such as raccoons or coyotes. Avoid dog parks, boarding facilities, and group puppy classes until 1 to 2 weeks after the final puppy vaccine dose. Puppy socialization classes that require current vaccination documentation for all attendees are a safer option than unsupervised dog park exposure during the vulnerable window.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles